What is Fred Aslan’s ARTV share ownership after these transactions?

After the reported transactions, Fred Aslan directly owned 1,562,198 ARTV common shares. This figure reflects the net position following the restricted stock unit award acquisition and the share withholding for income tax obligations related to RSU vesting.

Artiva Biotherapeutics (ARTV) CEO gets RSU grant, withholds shares for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics reported insider equity activity by President and CEO Fred Aslan. He acquired 366,850 shares of common stock through a restricted stock unit award granted under the company’s 2024 Equity Incentive Plan, and 14,600 shares were withheld at $4.00 per share to cover income tax obligations from vesting. Following these transactions, he directly owned 1,562,198 common shares.

Insider Trade Summary

Net Buyer: 352,250 shares

Net Buy 2 txns

Insider Aslan Fred

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	366,850	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	14,600	$4.00	$58K

Holdings After Transaction: Common Stock — 1,562,198 shares (Direct)

Footnotes (2)

F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/18/2026 - 06:48 PM

FAQ

What insider transactions did ARTV CEO Fred Aslan report on this Form 4?

Fred Aslan reported both an equity grant and a tax-related share disposition. He received 366,850 common shares via a restricted stock unit award, while 14,600 shares were withheld by Artiva Biotherapeutics to satisfy income tax obligations tied to RSU vesting.

How many Artiva Biotherapeutics (ARTV) shares did the CEO acquire?

The CEO acquired 366,850 shares of Artiva Biotherapeutics common stock. These shares came from a restricted stock unit award granted under the company’s 2024 Equity Incentive Plan, representing stock-based compensation rather than an open-market purchase of shares.

Why were 14,600 ARTV shares disposed of in the Form 4 filing?

14,600 Artiva Biotherapeutics shares were withheld to cover income tax obligations. The filing states these shares were retained by the company to satisfy taxes associated with the vesting of restricted stock unit awards, a common method of tax withholding for equity compensation.

Were the ARTV CEO’s transactions open-market buys or sales?

The reported ARTV transactions were equity compensation and tax withholding, not market trades. One transaction was a grant of restricted stock units at no cost, and the other was a disposition of shares withheld by the issuer to satisfy tax liabilities.

Under which plan was the ARTV CEO’s restricted stock unit award granted?

The restricted stock unit award was granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan. The Form 4 footnote specifies that the 366,850-share award is tied to this plan, indicating it is part of the company’s standard equity compensation program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		A		366,850⁽¹⁾	A	$0	1,576,798	D
Common Stock	02/15/2026		F		14,600⁽²⁾	D	$4	1,562,198	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR